Next Phase Newsletter

A London-based fund is focused on investing in advanced therapeutics. The firm invests both publicly and privately throughout the US, and Europe. For private deals, the firm makes equity deals in early-stage biotech therapeutic companies. The firm typically looks to make 8-10 deals in the private sector through each yearly cycle and typically allocates between $1M – $5M in each deal. The firm typically follows on these investments, preferring not to lead. The firm typically invests in seed and Series A rounds.

The firm is currently seeking biotech therapeutics that are considered advanced therapeutics. Examples of some therapies that the firm considers as advanced therapies are cell therapies and gene therapies. Currently, the firm is interested in immuno-oncology therapeutics, but is not interested in checkpoint inhibitors. For these therapeutics companies, they prefer that the asset is currently pre-clinical, in Phase I, or ready for phase II. The firm is agnostic in terms of specific indications.

The firm focuses on investing in companies located in the European Union, but typically finds that a good amount of their deals are based in the United States. The firm is open to other geographies, but has yet to see a deal that is particularly interesting to them from other areas.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A family office based in the US Southeast invests in healthcare in addition to other sectors. The firm makes equity investments ranging from early stage to full on commercialization, but also provides debt and convertible loan financing. The firm generally looks for USA-based opportunities but may consider deals outside of the USA and has a track record of working with companies globally. The firm seeks to make approximately 6-10 investments per year.

In the life sciences, the family office has a strong interest in medical device and diagnostic companies. The firm considers healthcare IT opportunities to a lesser degree, and will not consider biopharma companies for the most part. The family office is open to devices of all FDA regulatory pathways including 510k and PMA. The family office is very opportunistic regarding the company’s stage of development and will consider products that are both on- and off-market.

The family office is looking for privately held companies backed by an experienced management team. Companies should have a strong exit strategy, including having a direct line of contact with strategic or financial buyers. The firm is open to both leading and co-investing in a financing round.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A recently formed venture capital firm is focusing on the big-data aspect of personalized diagnostics. The firm is seeking early-stage companies raising seed to Series B rounds. The firm has a $200M target fund and seeks to make 15 –20 new investments within the year. The firm seeks to make $2M – $4M initial investments per company, but will make smaller initial seed investments. The firm prefers to be actively involved in their portfolio companies, and therefore prefers companies based near the west coast, though is open to other U.S.-based companies.

The firm is focused on early-detection diagnostics, such as discovering cancer when it is still monogenetic versus heterogeneous and already invaded in other parts of the body or detecting Alzheimer’s 8-10 years before dementia symptoms are present. The firm is interested in point-of-care diagnostics (for influenza A/B/bacterial, etc.) that can diagnose specifically and efficiently. The firm is especially interested in technology with a big-data component, and involved in genomics and personalized medicine to provide the right treatment as early as possible. DigitalDx seeks preclinical to clinical-stage technology, though will also look later-stage depending on the opportunity.

The firm requires a smart management team that is diverse in knowledge, and a company with good IP that may come from a leading institution. The firm will usually seek early-stage companies with less than half a dozen people.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.